Bioatla presents phase 2 ozuriftamab vedotin (oz-v) clinical trial data demonstrating compelling antitumor activity in hpv-associated oropharyngeal squamous cell carcinoma (hpv+ opscc) at the 1.8 mg/kg q2w dosing regimen

45% overall response rate (orr) and a 100% disease control rate (dcr) in hpv+ opscc patients treated with a median of 3 prior lines of therapy marked unmet need exists in 2l+ hpv+ opscc patients; standard of care agents (methotrexate, docetaxel, or cetuximab) report an orr of 3.4% plan to finalize phase 3 trial design in 2l+ hpv+ opscc with the u.s. food and drug administration (fda) san diego, june 02, 2025 (globe newswire) -- bioatla, inc. (nasdaq: bcab) (the “company”), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced data in a poster titled, “phase 2 trial of ozuriftamab vedotin (oz-v), a conditionally binding cab-ror2-adc, in patients with heavily pretreated squamous cell carcinoma of the head and neck.” the poster will be presented today at the 2025 american society of clinical oncology (asco) annual meeting at the mccormick place convention center in chicago, illinois.
BCAB Ratings Summary
BCAB Quant Ranking